Andira Pharmaceuticals

About Andira Pharmaceuticals

Andira Pharmaceuticals is a cannabinoid-focused biopharmaceutical company dedicated to developing innovative therapeutics and medical devices to address healthcare-associated infections (HAI), cancer treatment, and post-surgical pain management. Their mission is to improve lives and transform the future of healthcare through breakthrough pharmaceutical innovation and the synergistic properties of cannabinoids.

Products & Services

Silvanex™ Flex for Advanced Wound Care:A medical device designed for advanced wound care to prevent infections.

Silvanex™ IV Site for IV Insertion Sites:A medical device focused on infection control at IV insertion sites.

Silvanex™ Topical for Surgical Site Infection (SSI):A therapeutic product aimed at preventing surgical site infections.

AND-259 for DCIS Breast Cancer:A targeted therapeutic for the treatment of ductal carcinoma in situ (DCIS) breast cancer.

AND-254 for Mastectomy Pain:A therapeutic for managing pain following mastectomy procedures.

Specialties

Cannabinoid Therapeutics Hospital Infection Control Cancer Treatment Post-Surgical Pain Management

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Offering T: - FT: Equity Offering	A: 5000000 MR: - FA: up to $5 million FAN: 5000000	D: 2023-06-14 FD: 2023-06-14	1 investors

Equity Offering Latest

2023-06-14

$5.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dana Lambert

entrepreneur and biopharmaceutical executive

A

Ammad Shorbaji

VP, Regulatory Affairs

E

Ethan Russo

MD, Board-certified Neurologist, Psychopharmacology Researcher, and Author

J

Janette Lyons

Chief Financial Officer

E

Evelina Rubinchik

PhD

D

Dale Cameron

PhD, MCIC, PChem

View 12 more team members with Pro

Unlock Full Team Directory

Recent News